DRUG · Mapped RxNorm record
carboplatin
Normalized identity: carboplatinView linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Combination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
NCT00041054
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
etoposide
Normalized identity: etoposideView linked drug · Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
exisulind
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedCombination Chemotherapy and Exisulind in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Lung Cancerverified · MONDO: lung cancer
Interventions
carboplatinDRUG · verified · RxNorm: carboplatin
etoposideDRUG · verified · RxNorm: etoposide
exisulindDRUG
Sponsors & collaborators
Alliance for Clinical Trials in Oncologylead sponsor
National Cancer Institute (NCI)collaborator
Mapped research locations
ChicagoIllinois, United States4New YorkNew York, United States3St LouisMissouri, United States3Washington D.C.District of Columbia, United States3SyracuseNew York, United States3DallasTexas, United States2BaltimoreMaryland, United States2San FranciscoCalifornia, United States2DurhamNorth Carolina, United States2MinneapolisMinnesota, United States2Las VegasNevada, United States2Winston-SalemNorth Carolina, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00041054 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.